Literature DB >> 29854840

Melittin Constrains the Expression of Identified Key Genes Associated with Bladder Cancer.

Zidan Jin1,2, Jie Yao3, Nianlin Xie4, Libo Cai5, Shuai Qi6, Zhan Zhang1, Bai Li1.   

Abstract

This work is aimed at investigating the effect of melittin on identified key genes in bladder cancer (BC) and further providing a theoretical basis for BC treatment. GSE35014 downloaded from the Gene Expression Omnibus (GEO) database was used to screen differentially expressed genes (DEGs) in BC cells and control. Results showed that a total of 389 upregulated and 169 downregulated genes were identified. Subsequently, GO analysis, KEGG pathway enrichment analysis, and PPI network analysis were employed to disclose the crucial genes and signaling pathways involved in BC. Fifteen module-related DEGs and their associated signaling pathways were obtained according to the PPI network and modular analyses. Based on the analysis of articles retrieved in the PubMed database, we found that melittin could induce apoptosis and constrain the progression of tumor cells as a result of regulating critical cancer-related signaling pathways, such as PI3K-Akt and TNF signaling pathways. Furthermore, PI3K-Akt and TNF signaling pathways were also found to be associated with module-related DEGs according to biological analyses. At last, qRT-PCR analysis demonstrated that melittin could constrain the expression of module-related DEGs (LPAR1, COL5A1, COL6A2, CXCL1, CXCL2, and CXCL3) associated with PI3K-Akt and TNF signaling pathways in BC cells. Functional assays revealed that melittin could constrain the proliferative and migrated abilities of BC cells. Conjointly, these findings provide a theoretical basis for these six genes as drug-sensitive markers of melittin in BC treatment.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29854840      PMCID: PMC5960535          DOI: 10.1155/2018/5038172

Source DB:  PubMed          Journal:  J Immunol Res        ISSN: 2314-7156            Impact factor:   4.818


  50 in total

Review 1.  Microarray data analysis: from disarray to consolidation and consensus.

Authors:  David B Allison; Xiangqin Cui; Grier P Page; Mahyar Sabripour
Journal:  Nat Rev Genet       Date:  2006-01       Impact factor: 53.242

2.  Expression of antimicrobial peptides has an antitumour effect in human cells.

Authors:  D Winder; W H Günzburg; V Erfle; B Salmons
Journal:  Biochem Biophys Res Commun       Date:  1998-01-26       Impact factor: 3.575

3.  Melittin inhibits tumor growth and decreases resistance to gemcitabine by downregulating cholesterol pathway gene CLU in pancreatic ductal adenocarcinoma.

Authors:  Xinjing Wang; Jing Xie; Xiongxiong Lu; Hongzhe Li; Chenlei Wen; Zhen Huo; Junjie Xie; Minmin Shi; Xiaomei Tang; Hao Chen; Chenghong Peng; Yuan Fang; Xiaxing Deng; Baiyong Shen
Journal:  Cancer Lett       Date:  2017-04-17       Impact factor: 8.679

4.  Treatment options and predictive factors for recurrence and cancer-specific mortality in bladder cancer after renal transplantation: A multi-institutional analysis.

Authors:  O Rodriguez Faba; J Palou; H Vila Reyes; L Guirado; A Palazzetti; P Gontero; F Vigués; J Garcia-Olaverri; J M Fernández Gómez; J Olsburg; C Terrone; A Figueiredo; J Burgos; E Lledó; A Breda
Journal:  Actas Urol Esp       Date:  2017-11-08       Impact factor: 0.994

Review 5.  Melittin, a major peptide component of bee venom, and its conjugates in cancer therapy.

Authors:  Islam Rady; Imtiaz A Siddiqui; Mohamad Rady; Hasan Mukhtar
Journal:  Cancer Lett       Date:  2017-05-20       Impact factor: 8.679

6.  Melittin suppresses EGF-induced cell motility and invasion by inhibiting PI3K/Akt/mTOR signaling pathway in breast cancer cells.

Authors:  Yun-Jeong Jeong; Yongsoo Choi; Jae-Moon Shin; Hyun-Ji Cho; Jeong-Han Kang; Kwan-Kyu Park; Jung-Yoon Choe; Young-Seuk Bae; Sang-Mi Han; Cheorl-Ho Kim; Hyeun-Wook Chang; Young-Chae Chang
Journal:  Food Chem Toxicol       Date:  2014-03-25       Impact factor: 6.023

7.  Melittin induces PTCH1 expression by down-regulating MeCP2 in human hepatocellular carcinoma SMMC-7721 cells.

Authors:  Xiaoqin Wu; Bin Zhao; Yahui Cheng; Yang Yang; Cheng Huang; Xiaoming Meng; Baoming Wu; Lei Zhang; Xiongwen Lv; Jun Li
Journal:  Toxicol Appl Pharmacol       Date:  2015-07-17       Impact factor: 4.219

8.  Expression microarray meta-analysis identifies genes associated with Ras/MAPK and related pathways in progression of muscle-invasive bladder transition cell carcinoma.

Authors:  Jonathan A Ewald; Tracy M Downs; Jeremy P Cetnar; William A Ricke
Journal:  PLoS One       Date:  2013-02-01       Impact factor: 3.240

9.  Suppression of Hepatic Epithelial-to-Mesenchymal Transition by Melittin via Blocking of TGFβ/Smad and MAPK-JNK Signaling Pathways.

Authors:  Ji-Hyun Park; Byoungduck Park; Kwan-Kyu Park
Journal:  Toxins (Basel)       Date:  2017-04-13       Impact factor: 4.546

10.  Melittin suppresses tumor progression by regulating tumor-associated macrophages in a Lewis lung carcinoma mouse model.

Authors:  Chanju Lee; Sung-Joo S Bae; Hwansoo Joo; Hyunsu Bae
Journal:  Oncotarget       Date:  2017-06-27
View more
  3 in total

Review 1.  Applications and evolution of melittin, the quintessential membrane active peptide.

Authors:  Shantanu Guha; Ryan P Ferrie; Jenisha Ghimire; Cristina R Ventura; Eric Wu; Leisheng Sun; Sarah Y Kim; Gregory R Wiedman; Kalina Hristova; Wimley C Wimley
Journal:  Biochem Pharmacol       Date:  2021-09-17       Impact factor: 6.100

Review 2.  Pharmacological effects and mechanisms of bee venom and its main components: Recent progress and perspective.

Authors:  Peiying Shi; Shihui Xie; Jiali Yang; Yi Zhang; Shuo Han; Songkun Su; Hong Yao
Journal:  Front Pharmacol       Date:  2022-09-27       Impact factor: 5.988

3.  Melittin inhibits proliferation, migration and invasion of bladder cancer cells by regulating key genes based on bioinformatics and experimental assays.

Authors:  Jie Yao; Zhan Zhang; Sheng Li; Bai Li; Xing-Huan Wang
Journal:  J Cell Mol Med       Date:  2019-11-05       Impact factor: 5.295

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.